EP1496931A4 - Verfahren zur behandlung einer autoimmunkrankheit mit einem löslichen ctla4-molekül und einem dmard oder nsaid - Google Patents

Verfahren zur behandlung einer autoimmunkrankheit mit einem löslichen ctla4-molekül und einem dmard oder nsaid

Info

Publication number
EP1496931A4
EP1496931A4 EP03747047A EP03747047A EP1496931A4 EP 1496931 A4 EP1496931 A4 EP 1496931A4 EP 03747047 A EP03747047 A EP 03747047A EP 03747047 A EP03747047 A EP 03747047A EP 1496931 A4 EP1496931 A4 EP 1496931A4
Authority
EP
European Patent Office
Prior art keywords
dmard
nsaid
treating
methods
autoimmune disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03747047A
Other languages
English (en)
French (fr)
Other versions
EP1496931A1 (de
Inventor
Robert Cohen
Suzette Carr
David Hagerty
Robert J Peach
Jean-Claude Becker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP1496931A1 publication Critical patent/EP1496931A1/de
Publication of EP1496931A4 publication Critical patent/EP1496931A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03747047A 2002-04-19 2003-04-18 Verfahren zur behandlung einer autoimmunkrankheit mit einem löslichen ctla4-molekül und einem dmard oder nsaid Withdrawn EP1496931A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37385202P 2002-04-19 2002-04-19
US373852P 2002-04-19
US40724602P 2002-08-30 2002-08-30
US407246P 2002-08-30
PCT/US2003/012356 WO2003088991A1 (en) 2002-04-19 2003-04-18 Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid

Publications (2)

Publication Number Publication Date
EP1496931A1 EP1496931A1 (de) 2005-01-19
EP1496931A4 true EP1496931A4 (de) 2009-07-01

Family

ID=29254538

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03747047A Withdrawn EP1496931A4 (de) 2002-04-19 2003-04-18 Verfahren zur behandlung einer autoimmunkrankheit mit einem löslichen ctla4-molekül und einem dmard oder nsaid

Country Status (4)

Country Link
EP (1) EP1496931A4 (de)
AU (1) AU2003243152A1 (de)
CA (1) CA2482042A1 (de)
WO (1) WO2003088991A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006231622B2 (en) 2005-04-06 2012-07-05 Bristol-Myers Squibb Company Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules
EP1954836B1 (de) * 2005-11-08 2014-01-08 Sarepta Therapeutics, Inc. Verbindung zur Immununterdrückung und Behandlungsverfahren
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
TWI423986B (zh) 2005-12-20 2014-01-21 必治妥美雅史谷比公司 組合物及製造組合物之方法
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
WO2007143174A2 (en) 2006-06-01 2007-12-13 The Regents Of The University Of California Combination therapy method and formulation
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
EP2699258A4 (de) * 2011-04-15 2014-10-29 Us Sec Dep Of Health And Human Services Aav-vermittelter ctla-4-gentransfer zur behandlung des sjögren-syndroms
EP2709653B1 (de) 2011-04-20 2017-11-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Aav-vermittelter exendin-4-gentransfer in die speicheldrüsen zum schutz vor diabetes oder adipositas
US10166299B2 (en) 2012-08-31 2019-01-01 The United States Of America As Represented By The Secretary Dept. Of Health And Human Services National Institutes Of Health AAV mediated aquaporin gene transfer to treat Sjogren's syndrome
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
US9757372B2 (en) * 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002638A2 (en) * 2000-07-03 2002-01-10 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble ctla4 molecule

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
ATE271066T1 (de) * 2000-05-26 2004-07-15 Bristol Myers Squibb Co Lösliche mutante ctla4 moleküle und deren verwendung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002638A2 (en) * 2000-07-03 2002-01-10 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble ctla4 molecule

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MORELAND L W ET AL: "COSTIMULATORY BLOCKADE IN PATIENTS WITH RHEUMATOID ARTHRITIS", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 46, no. 6, 1 June 2002 (2002-06-01), pages 1470 - 1479, XP009066947, ISSN: 0004-3591 *
See also references of WO03088991A1 *

Also Published As

Publication number Publication date
WO2003088991A1 (en) 2003-10-30
EP1496931A1 (de) 2005-01-19
WO2003088991A9 (en) 2004-02-05
AU2003243152A1 (en) 2003-11-03
CA2482042A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
EP1496931A4 (de) Verfahren zur behandlung einer autoimmunkrankheit mit einem löslichen ctla4-molekül und einem dmard oder nsaid
AU2003216507A8 (en) Methods, systems, and software for identifying functional bio-molecules
EP1556057A4 (de) Mittel und verfahren zur verstärkung der knochenbildung
ZA200410191B (en) Systems and methods for secure biometric authentification
EP1638432A4 (de) Werkzeugaufbewahrungssystem und verfahren
AU2003297908A8 (en) Articulated elements and methods for use
AU2003300783A8 (en) Vascular assist device and methods
AU2003228850A8 (en) Single trial detection in encephalography
PL383616A1 (pl) Środki wiążące inhibitujące miostatynę
AU2003283786A8 (en) Surgical tools and techniques for stimulation
AU2003225743A8 (en) Method and system for managing software licenses
AU2003285117A8 (en) Multiple-entity transaction systems and methods
IL169187A0 (en) Fungicides based on nitrogen-containing heterocycles
AU2003303352A1 (en) Chip reader for biochips and associated methods
AU2003268800A1 (en) Barking device and barking tool
EP1495449A4 (de) System und verfahren zum authentifizieren von artikeln
EP1543324A4 (de) Verfahren und zusammensetzungen zur implantation von funktionalen schleifen in ein protein
GB0201498D0 (en) Materials and methods for treating cancer
EP1545554A4 (de) Verfahren und zusammensetzungen zur behandlung von diabetes mellitus
AU2003227861A8 (en) Protein involved in cancer
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
AU2003301348A1 (en) Compositions and methods for diagnosing and treating autoimmune disease
HK1073370A1 (en) Method, system and software for journaling system objects
AU2003275240A8 (en) Methods and compositions for soluble cpg15
GB0224436D0 (en) Polypetides methods and means

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20090604

17Q First examination report despatched

Effective date: 20100614

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101026